Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes

Salleras, L.; Domı́nguez, Àngela; Vidal, Josep; Plans, Pere; Salleras, M.; Taberner, J.L.

doi:10.1016/s0264-410x(00)00178-x

Cited by 71 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Nearly all people aged ≥50 y are infected by the virus. This means that 100% of the adult and elderly population of Catalonia harbor the VZV in their sensorial, dorsal and cranial ganglia, a situation that persists as long as cellular immunity against the virus is maintained.…”

Section: Introductionmentioning

confidence: 99%

Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Salleras

Salvador

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Salleras

Salvador

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The high seroprevalence rates found are comparable and even higher than those observed in the United States (19 (41) and Spain (34). High seroprevalence levels were also observed in other countries of Latin America, such as Brazil, where 95.5% of individuals aged 16 to 20 years were seropositive (9), or Mexico, where 91.6% of people 20 to 24 years old were seropositive (3).…”

Section: Discussionmentioning

confidence: 65%

“…Second, our study included only the female population, and its results may not be generalized to the total population. Although some reports suggest that women have slightly higher rates of VZV susceptibility than men do (9,23), which is attributed to a higher contact of women with children, significant differences by gender have not been found in most seroprevalence studies conducted in different parts of the world (3,6,17,28,29,31,34). This is the first study to show the serological and molecular epidemiology of varicella in different areas of Argentina.…”

Section: Discussionmentioning

confidence: 80%

“…Although in some studies, socioeconomic variables (e.g., social class, educational level) do not seem to help predict varicella antibody status (1,24,28,34), varicella seroprevalence has been associated with socioeconomic factors in children in Brazil and England (9,32). The lower immunity observed in women living in households with less than two persons per bedroom in Argentina is consistent with the results of a study conducted in Lebanon, where coming from homes with a smaller number of rooms and smaller families were predictors of a lack of immunity to varicella (29).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Varicella Seroprevalence and Molecular Epidemiology of Varicella-Zoster Virus in Argentina, 2002

et al. 2004

View full text Add to dashboard Cite

There is limited data on immunity against varicella-zoster virus (VZV) in adults in different parts of Argentina, and it is not known which VZV strains are circulating in Argentina. The objectives of this study were as follows: (i) to evaluate seroprevalence of varicella among adults, assessing the accuracy of clinical history and determining the sociodemographic factors associated with seropositivity; and (ii) to determine the VZV strains circulating in Argentina. A cross-sectional serological survey enrolling 2,807 women aged 15 to 49 years attending public health-care settings in four cities in Argentina (i.e., Buenos Aires, Salta, Mendoza, and Rosario) and one rural area was conducted from August to November 2002. Specimens for identification of VZV strains were obtained from vesicular lesions from 13 pediatric patients with varicella from different areas of the country. PCR amplification was used for genotyping. The overall seroprevalence of varicella antibodies was 98.5% (95% confidence interval, 98.0 to 98.9), ranging from 97.2% in central Buenos Aires to 99.3% in southern Buenos Aires and Salta. Varicella seroprevalence increased with age. Crowding and length of residence in the same place were associated with seropositivity. The positive predictive value of varicella history for immunity to varicella was 99.4%; however, the negative predictive value was 2.5%. The European genotype was identified in all viral specimens. In Argentina, seroprevalence in women more than 15 years old was high regardless of the area of residence. Negative or uncertain varicella history was not a good predictor of immunity. VZV genotype was stable in all areas of the country.

show abstract

“…Another Swiss study documented a seroprevalence of 96.55% in 13-15-year-old adolescents [21]. VZV seroprevalence reached over 90% among 8 to 9-year olds in Germany [40] and 91.8% among 10 to 14-year olds in Spain (Catalonia) [33]. Two data sets provide lower prevalences (i.e.…”

Section: Discussionmentioning

confidence: 99%

The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium)

Thiry

Beutels

Shkedy

et al. 2002

European Journal of Pediatrics

View full text Add to dashboard Cite

since varicella-zoster virus predominantly affects very small children and is generally perceived as benign, the required high coverage rate of a universal childhood varicella vaccination programme may be hard to attain. Adolescent strategies can minimise the population risks involved but the accuracy of non positive antecedents of chickenpox needs to be documented to assess the efficiency of such strategies.

show abstract

Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes

Cited by 71 publications

References 34 publications

Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Herpes zoster and postherpetic neuralgia in Catalonia (Spain)

Varicella Seroprevalence and Molecular Epidemiology of Varicella-Zoster Virus in Argentina, 2002

The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium)

Contact Info

Product

Resources

About